Introduction
Brand name: Risewest‑CP 10
Manufacturer: Astemax Biotech
Composition: Rosuvastatin 10 mg + Aspirin 75 mg (enteric‑coated) + Clopidogrel 75 mg tablet
Risewest‑CP 10 is a triple‑cardioprotection fixed‑dose combination tablet formulated for secondary prevention and high‑risk primary prevention of atherothrombotic events. It integrates lipid‑lowering, anti‑inflammatory, and dual‑antiplatelet actions in one once‑daily dose.
Key ingredients and mechanism
Rosuvastatin 10 mg
Statin that lowers LDL‑cholesterol, total cholesterol, and triglycerides while stabilising atherosclerotic plaque and reducing cardiovascular risk.
Aspirin 75 mg (enteric‑coated)
Cyclooxygenase‑1 inhibitor that irreversibly blocks platelet aggregation, reducing thrombus formation in arterial vessels.
Clopidogrel 75 mg
P2Y₁₂ ADP‑receptor antagonist that provides additional antiplatelet effect, enhancing protection in acute coronary syndrome (ACS), post‑stent, or post‑MI settings.
Main indications
Post‑myocardial infarction, post‑stent, post‑coronary‑angioplasty, and other high‑risk CAD/PAD patients as part of dual antiplatelet therapy (DAPT) plus statin.
Stroke and high‑risk atherosclerotic patients where simultaneous control of cholesterol and thrombosis is desired.
Typical use and precautions
Usual dose: 1 Risewest‑CP 10 tablet once daily, usually in the morning, with food, strictly under cardiologist/physician guidance.
Astemax can position Risewest‑CP 10 as a WHO‑GMP‑oriented, once‑daily “triple‑therapy” tablet for cardiology and high‑risk‑diabetes‑care settings, improving patient compliance and simplifying polypharmacy in chronic CV‑risk management.
